Value of an inhalational model of invasive aspergillosis

References

• Shibuya K, Naoe S, Yamaguchi H. Animal models of A. fumigatus infections. Contrib Microbiol 1999; 2: 130–138.
   PubMedGoogle Scholar
• Yamaguchi Y. Opportunistic fungal infections. In: Miyaji M (ed.). Animal Models in Medical Mycology. Boca Raton, FL: CRC Press, 1987: 101–158.
   Google Scholar
• Schmidt A. Animal models of aspergillosis — also useful for vaccination strategies? Mycoses 2002; 45: 38–40.
   PubMed Web of Science ®Google Scholar
• Sabetta JR, Miniter P, Andriole VT. The diagnosis of invasive aspergillosis by an enzyme-linked immunosorbent assay for circulating antigen. J Infect Dis 1985; 152: 946–953.
   Google Scholar
• Spreadbury CL, Krausz T, Pervez S, Cohen J. Invasive aspergil-losis: clinical and pathological features of a new model. J Med Vet Mycol 1989; 27: 5–15.
   PubMedGoogle Scholar
• Matsumoto S, Wakai Y, Nakai T, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Ant imicrob Agents Chemother 2000; 44: 619–621.
   PubMed Web of Science ®Google Scholar
• Shibuya K, Ando T, Wakayama M, et al. Pathological spectrum of invasive pulmonary aspergillosis: study of pulmonary lesions of 54 autopsies and the relationship between neutrophilic response and histologic features of lesions in experimental aspergillosis. Jap J Med Mycol 1997; 38: 175–181.
   Google Scholar
• Shibuya K, Takaoka M, Uchida K, et al. Histopathology of experimental invasive pulmonary aspergillosis in rats: pathologi-cal comparison of pulmonary lesions induced by specific virulent factor deficient mutants. Microb Pathol 1999; 27: 123–131.
   PubMed Web of Science ®Google Scholar
• Merkow LP, Epstein SM, Sidransky H, et al. The pathogenesis of experimental pulmonary aspergillosis. An ultrastructural study of alveolar macrophages after phagocytosis of A. flavus spores in vivo. Am J Pathol 1971; 62: 57–74.
   Google Scholar
• Schlitzer RL, Chandler FW, Larsh HW. Primary acute histoplas-mosis in guinea pigs exposed to aerosolized Histoplasma capsu-latum. Infect Immun 1981; 33: 575–582.
   Google Scholar
• Woolums AR, Anderson ML, Gunther RA, et al. Evaluation of severe disease induced by aerosol inoculation of calves with bovine respiratory syncytial virus. Am J Vet Res 1999; 60: 473–480.
   PubMed Web of Science ®Google Scholar
• Heinen PP, van Nieuwstadt AP, Pol JM, et al. Systemic and mucosal isotype-specific antibody responses in pigs to experi-mental influenza virus infection. Viral Immunol 2000; 13: 237–247.
   PubMedGoogle Scholar
• Brooks JV, Orme IM. Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model. Ant imicrob Agents Chemother 1998; 42: 3047–3048.
   PubMedGoogle Scholar
• Yamagishi Y, Fujita J, Takigawa K, et al. Experimental pneumo-nia produced by clinical isolates of Pseudomonas cepacia in mice. Kansenshogaku Zasshi 1993; 67: 816–822.
   PubMedGoogle Scholar
• Canthaboo C, Xing D, Douglas A, Corbel M. Investigation of an aerosol challenge model as alternative to the intracerebral mouse protection test for potency assay of whole cell pertussis vaccines. Biologicals 2000; 28: 241–246.
   PubMed Web of Science ®Google Scholar
• Twisk-Meijssen MJ, Meenhorst PL, van Cronenburg BJ, et al. The course of Legionella pneumonia in guinea pigs after inhalation of various quantities of L. pneumophila . Immunobiol-ogy 1987; 176: 108–124.
   Google Scholar
• Coil JA, Dickerman JD, Boulton E. Increased susceptibility of splenectomized mice to infection after exposure to an aerosolized suspension of type III Streptococcus pneumoniae. Infect Immun 1978; 21: 412–416.
   Google Scholar
• Tang CM, Cohen J, Krausz T, et al. The alkaline protease of Aspergillus fumigatus is not a virulence determinant in two murine models of invasive pulmonary aspergillosis. Infect Immun 1993; 61: 1650–1656.
   PubMed Web of Science ®Google Scholar
• Sidransky H, Friedman L. The effect of cortisone and antibiotic agents on experimental pulmonary aspergillosis. Am J Pathol 1959; 35: 169–184.
   PubMedGoogle Scholar
• Sidransky H, Verney E. Experimental aspergillosis. Lab Invest 1962; 11: 1172–1183.
   Web of Science ®Google Scholar
• Epstein SM, Verney E, Miale TD, Sidransky H. Studies on the pathogenesis of experimental pulmonary aspergillosis. Am J Pathol 1967; 51: 769–788.
   PubMed Web of Science ®Google Scholar
• Ford S, Friedman L. Experimental study of the pathogenicity of Aspergilli for mice. J Bacteriol 1967; 94: 928–933.
   PubMed Web of Science ®Google Scholar
• Sandhu DK, Sandhu RS, Damodaran VN, Randhawa HS. Effect of cortisone on bronchopulmonary aspergillosis in mice exposed to spores of various Aspergillus species. Sabouraudia 1970; 8: 32–38.
   PubMedGoogle Scholar
• Kothary MH, Chase T Jr, MacMillan JD. Correlation of elastase production by some strains of ilspergillus fumigatus with ability to cause pulmonary invasive aspergillosis in mice. Infect Immun 1984; 43: 320–325.
   PubMed Web of Science ®Google Scholar
• Le Conte P, Joly V, Saint-Julien L, et al. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis. Am Rev Resp Dis 1992; 145: 424–429.
   Google Scholar
• Cacciapuoti A, Loebenberg D, Corcoran E, et al. In vitro and in vivo activities of SCH 56592 (Posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000; 44: 2017-2022.
   Google Scholar
• Menzel F Jr, Jackson C, Patera A, et al. Combination treatment of posaconazole and granulocyte colony-stimulating factor against Aspergillus in a mouse pulmonary infection model. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego. Washing-ton, 2002: abstract M–858.
   Google Scholar
• Hinners RG, Burkart JK, Contner GL. Animal exposure cham-bers in air pollution studies. Arch Environ Health 1966; 13: 609–615.
   PubMed Web of Science ®Google Scholar
• Whitehead GS, Walker JK, Berman KG, et al. Allergen-induced airway disease is mouse strain dependent. Am J Physiol Lung Cell Mol Physiol 2003; 285: L32—L42.
   Google Scholar
• Cox GM, Harrison TS, McDade HC, et al. Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun 2003; 71: 173–180.
   PubMed Web of Science ®Google Scholar
• Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45: 3474–3481.
   PubMed Web of Science ®Google Scholar
• Brain JD, Knudson DE, Sorokin SP, Davis MA. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res 1976; 11: 13–33.
   PubMed Web of Science ®Google Scholar
• Pritchard JN, Holmes A, Evans JC, et al. The distribution of dust in the rat lung following administration by inhalation and by single intratracheal instillation. Environ Res 1985; 36: 268–297.
   PubMed Web of Science ®Google Scholar
• Oberdorster G, Cox C, Gelein R. Intratracheal instillation versus intratracheal inhalation of tracer particles for measuring lung clearance function. Exp Lung Res 1997; 23: 17–34.
   Google Scholar
• Wheat U. Combination therapy for aspergillosis: is it needed, and which combination? J Infect Dis 2003; 187: 1831-1833.
   Google Scholar
• Eisenstein DJ, Biddinger PW, Rhodes JC. Experimental murine invasive pulmonary aspergillosis. Am J Pathol 1989; 93: 510–515.
   Google Scholar
• Piggott WR, Emmons CW. Device for inhalation exposure of animals to spores. Proc Soc Exp Bio Med 1960; 103: 805–806.
   PubMedGoogle Scholar
• Sheppard DC, Filler SG, Rieg G, et al. Development of a clinically relevant, reproducible inhalational model of invasive aspergillosis. In: Program and Abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC, 2003: abstract M–372.
   Google Scholar
• Loebenberg D, Cacciapuoti A, Parmegiani R, et al. In vitro and in vivo activities of SCH 4247, the active enantiomer of the antifungal agent SCH 39304. Antimicrob Agents Chemother 1992; 36: 498–501.
   PubMedGoogle Scholar